Europe Sleeping Aids Market Analysis, Size, Growth and Demand, 2022

The European sleeping aids market was valued at $14.8 billion in 2015 and is forecasted to grow at a CAGR of 6.2% during 2016-2022. Various sleep disorders are hampering the lives of people in the region, due to increasing tobacco and alcohol consumption, rising aging population, growing population base working in night shifts and changing lifestyle habits of the Europeans. Sleep disorders such as insomnia, sleep apnea, restless legs syndrome, narcolepsy, sleep walking and others greatly affect the population base in the European region.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/europe-sleeping-aids-market/report-sample

Sleeping aids namely mattress & pillow, sleep laboratories, medication, sleep apnea devices and others are largely used for the above-mentioned sleeping disorders. Mattress & pillows held the largest share in the European sleeping aids market and contributed 43% in 2015. Amongst all the sleep related problems people are being majorly affected by insomnia and sleep apnea in the Europe.

Increasing awareness about sleep disorders and risks associated with them, by various organizations such as the British Sleep Society and Survey Sleep Research Center has been driving the demand of the sleeping aids products in the region. According to the Eurostat, aging population is a long-term trend in the region, this is also a key factor driving the demand for sleeping aids in the region. The share of population aged 65 years and over is increasing in every European Union (EU) member state. During the period 2016 to 2080 the aging population is expected to account for a share of 29.1% of the EU-28 population compared to 19.2% in 2016.

Explore Report at: https://www.psmarketresearch.com/market-analysis/europe-sleeping-aids-market

Some of the key players operating in the European sleeping aids industry are Sanofi S.A., Koninklijke Philips N.V., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Roche Holding AG, AstraZeneca plc, Becton, Dickinson and Company, Drive Medical Ltd., Somnomedics Gmbh and Cardinal Health.